الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 182 |  |  |
| | | from | 182 | | |
Abstract
The incidence of diabetes is escalating worldwide and, consequently, this has become a major health care problem. Moreover, both type I and type II diabetes are associated with significantly accelerated rates of several complications. Inosine is an endogenous purine exerts immunomodulatory and anti-inflammatory effects; include inhibition of pro- inflammatory cytokine and chemokine production, enhancement of anti-inflammatory cytokine interleukins.
This study was designed to investigate and achieve preventive and therapeutic effects daily of inosine on type I diabetes induced by 24 Streptozotocin in male rats. Rats were divided into four groups: group 1 (control), group 2 (diabetic untreated), group 3 treated with inosine after induction of diabetes (therapeutic group), and group 4 treated with inosine before induction of diabetes 26 (preventive group). Diabetes was induced in groups 2-5 by a single dose of 40 mg/kg Streptozotocin (STZ) in citrate buffer pH 4.5.Two days after STZ treatment, development of diabetes in the experimental groups was confirmed by measuring blood glucose.
Preventive group showed significantly reduced nitric oxide, malondialdehyde and IL-6 concentrations and increase 29 activity of superoxide dismutase, and catalase, more than
2014
those in therapeutic group, compared to diabetic group. Also, the elevated levels of urea, creatinine, liver function tests, and lipid profile in group 2 were improved significantly as a result of the treatment and prevention. These data support the proposal that inosine might represent a useful adjunct in the therapy of diabetes. Inosine exerts a therapeutic protective effect in diabetes by decreasing oxidative stress.